Alvit LCS Pharma

Alvit LCS Pharma Overview

Alvit LCS Pharma is a vertically integrated medical cannabis research and development company specializing in pharmaceutical-grade cannabis product development and drug-delivery technologies. The company's products include various types of tablets, sprays, and suppositories. Alvit controls the entire lifecycle of the cannabis drug-development process, including Good Agriculture Practice-controlled cultivation of proprietary cannabis clones, standardized extracts, preclinical evaluations, proprietary formulations, and first-in-human studies. In November 2018, Alvit LCS Pharma announced the merger of its cannabis growing activity into Intelicann, a cannabis cultivation facility in Israel that is publicly traded on the Tel Aviv Stock Exchange.

Cumulative Funding Raised Over Time ($)

Latest News

Jan 2, 2020 · www.healtheuropa.eu

Alvit: Europe's search for cannabis flowers comes to an end

Apr 8, 2019 · www.healtheuropa.eu

Cannabis-based products in a language doctors understand

Jan 24, 2019 · www.prnewswire.com

growth-positive

Alvit LCS Pharma Sponsors Cannabis Pavilion in Davos

Alvit LCS Pharma, a medical cannabis company, is a sponsor of Cannatechs Canada Cannabis House in Davos. The CEO presented at the event and expressed the companys commitment to nurturing key relationships and showcasing their products and technologies. The Canada Cannabis House pavilion includes notable presenters and attendees from the cannabis industry. Alvit LCS Pharma specializes in pharma grade products and drug delivery technologies, with a focus on standardized cannabis extracts that have undergone clinical trials. The company aims to provide doctors with the knowledge they need to effectively prescribe cannabis to patients.

PartnersCustomers

Oct 24, 2018 · www.prnewswire.com

growth-positive

Alvit LCS Pharma: Manufacturing and Licensing Agreement With Israel's Largest Medical Cannabis Company Bazelet

Bazelet, Israels largest Medical Cannabis Company, has signed a manufacturing and licensing agreement with Alvit LCS Pharma to manufacture, market, and sell Alvits line of pharma grade medical cannabis products in Israel and the EU. Bazelet will also collaborate with Alvit on the research and development of a new pharmaceutical drug for the treatment of Inflammatory Bowel Disease (IBD). This partnership strengthens Bazelets position in the Israeli Medical Cannabis market and expands its product offerings. Bazelets CEO, Meir Ariel, expressed excitement about the agreement and the potential benefits for patients. Alvit, an international leader in the development of products based on standardized cannabis extracts, will work with Bazelet to manufacture and distribute their products and develop an IBD product based on Bazelets unique API.

Partners

Funding

Team Members

4

Employees: 1-10

Web & Social Links

Locations

Yigal Alon 94, Tel-Aviv, Israel

Photos & Videos

2 item(s)

Alvit LCS Pharma Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info